Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 26,560 | 30,304 | 11,660 | 14,786 | 16,083 |
| Receivables | 106 | 14 | 250 | 23 | 40 |
| TOTAL | $27,335 | $31,102 | $12,515 | $15,601 | $16,758 |
| Non-Current Assets | |||||
| PPE Net | 3 | 175 | 200 | 224 | 247 |
| Intangibles | 493 | 507 | 521 | 535 | 411 |
| Other Non-Current Assets | 58 | 0 | 0 | 0 | 0 |
| TOTAL | $553 | $682 | $721 | $759 | $657 |
| Total Assets | $27,888 | $31,785 | $13,236 | $16,360 | $17,415 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 559 | 803 | 550 | 632 | 887 |
| Accrued Expenses | 401 | 2,221 | 2,332 | 1,893 | 1,642 |
| Other current liabilities | 11,520 | 9,338 | 11,727 | 8,052 | 6,823 |
| TOTAL | $15,342 | $12,876 | $15,140 | $11,124 | $9,704 |
| Non-Current Liabilities | |||||
| TOTAL | $58 | $82 | $106 | $129 | $152 |
| Total Liabilities | $15,399 | $12,958 | $15,245 | $11,253 | $9,856 |
| Shareholders' Equity | |||||
| Common Shares | 80,043 | 79,780 | 58,932 | 58,760 | 58,594 |
| Retained earnings | -88,324 | -80,498 | -78,153 | -69,545 | -65,242 |
| Other shareholders' equity | 20,771 | 19,545 | 17,212 | 15,892 | 14,208 |
| TOTAL | $12,489 | $18,826 | $-2,009 | $5,107 | $7,559 |
| Total Liabilities And Equity | $27,888 | $31,785 | $13,236 | $16,360 | $17,415 |